---
title: 'Manufacturing Daily Summary: What Happened on October 12, 2026'
headline: GSK commits more than $800 million to Pennsylvania expansion
description: A UK report warns that rising immunoglobulin demand and import reliance
  could strain supply.
url: https://thebench.bio/news/manufacturing/2026-10-12
topic: manufacturing
date: '2026-10-12'
covers:
- '2026-10-12'
date_published: '2026-10-12T12:02:28Z'
date_modified: '2026-10-12T12:02:28Z'
tags:
- Industry
sources: 2
publisher: TheBench.Bio
---

# Manufacturing Daily Summary: What Happened on October 12, 2026

**GSK commits more than $800 million to Pennsylvania expansion**

A UK report warns that rising immunoglobulin demand and import reliance could strain supply.

## Today in brief

GSK plans to spend more than $800 million expanding manufacturing and research at its Upper Merion, Pennsylvania, site. [1] A report funded by argenx says imports account for about 80% of UK immunoglobulin supply, while demand keeps rising. [2]

## GSK plans new manufacturing and research facilities in Pennsylvania

GSK plans to invest more than $800 million in its Upper Merion operations and build facilities for clinical and commercial supply. [1] The planned hub includes a biologics production site, an R&D pilot plant, a quality control laboratory, and a manufacturing science and technology hub. [1]

GSK plans to start removing existing buildings next year. [1] Pennsylvania officials expect the project to create more than 300 jobs over five years and retain about 4,500 existing GSK positions in the state. [1]

## Also worth knowing

- The Office of Health Economics report puts UK plasma collection at about 4.4 liters per 1,000 people, versus a European average of 14 liters. NHS Blood and Transplant targets 30–35% plasma self-sufficiency by 2030. [2]

## The day in numbers

- **More than $800 million**: GSK's planned investment in its Upper Merion, Pennsylvania, operations. [1]
- **About 80%**: Share of UK immunoglobulin supply that the Office of Health Economics report says is imported. [2]

## Also published

- [Trio become latest Symbiosis commercial additions](<https://pharmafile.com/appointments/trio-become-latest-symbiosis-commercial-additions/>), Pharmafile
- [The Manufacturing Issues That Continue to Contribute to Drug Shortages](<https://www.pharmexec.com/view/manufacturing-issues-continue-contribute-drug-shortages>), Pharmaceutical Executive
- [Perfusion for next generation biosimilars](<https://european-biotechnology.com/sponsored-publications/perfusion-for-next-generation-biosimilars/>), European Biotechnology
- [Every process is different. Not the platform.](<https://european-biotechnology.com/sponsored-publications/every-process-is-different-not-the-platform/>), European Biotechnology

## Sources

1. [GSK pledges $800M to add biologics production capabilities in Pennsylvania](<https://www.biospace.com/business/gsk-pledges-800m-to-add-biologics-production-capabilities-in-pennsylvania>), BioSpace, 2026-10-12
2. [UK immunoglobulin supply faces growing pressure, report warns](<https://pharmafile.com/news/uk-immunoglobulin-supply-faces-growing-pressure-report-warns/>), Pharmafile, 2026-10-12

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biospace.com/business/gsk-pledges-800m-to-add-biologics-production-capabilities-in-pennsylvania>
[2]: <https://pharmafile.com/news/uk-immunoglobulin-supply-faces-growing-pressure-report-warns/>